US launch for Tissue Regenix

HEALTHCARE technology company Tissue Regenix has launched a subsidiary company in the United States as part of its strategy to commercialise its innovative technology.

The York-based business has recruited Greg Bila from Kinetic Concepts Inc to be president of Tissue Regenix USA.

The company said its US arm would look to use its dCELL technology platform – which is used to treat wounds and help prevent rejection by the body – to target a number of areas. 

Work will focus initially on applying the dCELL to the treat a number of chronic diseases but, over time, could be developed for other applications including vascular repair, heart valve replacement and knee repair.

Antony Odell, managing director of Tissue Regenix, said: “This is a significant step in the development of Tissue Regenix. It is an excellent signal of the strength of TR’s proposition that we can attract people of Greg’s calibre and experience, we look forward to advancing our plans in the US with him at the helm.

“The United States presents an opportunity to establish our platform dCELL technology in a market potentially worth hundreds of millions of dollars.”